Stephens Consulting’s Achieve Life Sciences ACHV Stock Holding History

Stephens Consulting’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,000	Closed	-$9.45K	–	477
2025 Q3	$9.45K	Hold	3,000	–	–	﹤0.01%	228
2025 Q2	$6.78K	Hold	3,000	–	–	﹤0.01%	367
2025 Q1	$8.01K	Hold	3,000	–	–	﹤0.01%	345
2024 Q4	$10.6K	Hold	3,000	–	–	﹤0.01%	343
2024 Q3	$14.2K	Hold	3,000	–	–	﹤0.01%	301
2024 Q2	$14.1K	Hold	3,000	–	–	﹤0.01%	300
2024 Q1	$13.6K	Hold	3,000	–	–	﹤0.01%	285
2023 Q4	$12.4K	Hold	3,000	–	–	﹤0.01%	292
2023 Q3	$12.9K	Hold	3,000	–	–	0.01%	289
2023 Q2	$15.6K	Hold	3,000	–	–	0.01%	266
2023 Q1	$20.4K	Hold	3,000	–	–	0.01%	243
2022 Q4	$7.35K	Hold	3,000	–	–	﹤0.01%	334
2022 Q3	$9.9K	Buy	+3,000	New	+$14.3K	0.01%	334

Other funds holding ACHV

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Consulting's ACHV Position: Q4 2025 in Review

Stephens Consulting sold out of Achieve Life Sciences (ACHV) in Q4 2025, closing a stake of 3,000 shares — an estimated $9.45K sold.

Stephens Consulting first reported a position in ACHV in Q3 2022 and held it in 13 quarters. The position peaked at $20.4K in Q1 2023. 77 funds tracked by Wall St. Rank hold ACHV as of Q4 2025.

Stephens Consulting reported no remaining Achieve Life Sciences position as of Q4 2025 after selling out during the quarter.
Stephens Consulting sold 3,000 Achieve Life Sciences shares in Q4 2025, an estimated $9.45K.
Stephens Consulting first reported a position in Achieve Life Sciences in Q3 2022 and held it in 13 quarters.
Stephens Consulting's Achieve Life Sciences position peaked at $20.4K in Q1 2023.
77 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.